Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
E2F1
REST API REST API
Homo sapiens
E2F1 is differentially expressed in 285 experiments: 100 organism parts: bone marrow, kidney, ... (98 more);, 181 disease states: normal, acute lymphoblastic leukemia, ... (179 more);, 84 cell types 337 cell lines 41 compound treatments and 70 other conditions.
Synonyms RBBP3, RBP3
Orthologs E2f1 (Mus musculus)   E2f1 (Rattus norvegicus)   E2F1_CHICK (Gallus gallus)   E1BG94_BOVIN (Bos taurus)   E2F1 (Danio rerio)   E2f (Drosophila melanogaster)   e2f1 (Xenopus laevis)   E2F1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cyclin-dependent protein kinase activity, DNA binding, negative regulation of transcription, DNA-dependent, protein binding, apoptosis, regulation of transcription, DNA-dependent, cytoplasm, cell proliferation, transcription, DNA-dependent, positive regulation of gene expression, mitotic cell cycle, transcription corepressor activity, spermatogenesis, G1 phase of mitotic cell cycle, transcription factor binding, sequence-specific DNA binding, positive regulation of transcription from RNA polymerase II promoter, regulation of cell cycle, G1/S transition of mitotic cell cycle, nucleus, Rb-E2F complex, transcription factor complex, nucleoplasm, negative regulation of transcription from RNA polymerase II promoter, positive regulation of transcription, DNA-dependent, mitochondrion, mRNA stabilization, cellular response to hypoxia, forebrain development, cellular response to fatty acid, positive regulation of fibroblast proliferation, G2 phase of mitotic cell cycle, sequence-specific DNA binding transcription factor activity, regulation of G1/S transition of mitotic cell cycle, negative regulation of transcription involved in G1/S phase of mitotic cell cycle
InterPro Term E2F_TDP
UniProt Accession Q01094
Search EB-eye ENSG00000101412
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-MEXP-433, E-GEOD-3526, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, E-GEOD-4717, ... (39 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
MCF-7
3
E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
primary culture
2
E-GEOD-1657, E-GEOD-2450
AGS
2
E-GEOD-15460, E-MTAB-37
MOLT4
2
E-MTAB-62, E-MTAB-37
SW480
2
E-MEXP-1014, E-MTAB-37
331 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-13909, E-GEOD-20677, ... (40 experiments)

Factor Value U/D Experiments
2
2
E-TABM-145, E-TABM-130
CD71+ early erythroid
2
E-AFMX-5, E-TABM-145
epithelial cell
1
2
E-MEXP-2034, E-GEOD-4483, E-GEOD-10797
plasmablast
1
E-MEXP-2360
basophil
1
E-GEOD-3982
naive T cell
1
E-GEOD-1460
78 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (61 experiments)

Factor Value U/D Experiments
septic shock
2
E-GEOD-9692, E-GEOD-8121
chronic lymphocytic leukemia
2
E-GEOD-6691, E-GEOD-2466
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
cervical carcinoma
2
E-MTAB-62, E-MEXP-1331
glioblastoma
2
E-GEOD-4290, E-MTAB-37
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
175 more value(s).


Compound treatment

studied in E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (28 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-MEXP-1958, E-GEOD-3720, E-TABM-868
none
5
7
E-GEOD-20719, E-GEOD-1036, E-GEOD-412, E-GEOD-5824, E-TABM-782, ... (12 experiments)
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
bis [(+)-tartrato] diantimonate (III) dipotassium trihydrate
1
E-GEOD-6907
phoshate buffered saline
1
E-GEOD-3720
Cxcl12
1
E-GEOD-7307
35 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21374, E-GEOD-2034, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-MTAB-62

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-MEXP-421, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-20504, E-MEXP-1446, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (31 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, ... (6 experiments)

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636, ... (8 experiments)

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10797

RNAi
studied in E-GEOD-12438, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-16363

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-GEOD-1926

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-TABM-43, E-GEOD-4922 ... (5 experiments)

Processing time: 0.24 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM